Infliximab can induce a prolonged clinical remission and a decrease in thyroid hormonal requirements in a patient with SAPHO syndrome and hypothyroidism

Clin Rheumatol. 2008 Apr;27(4):533-5. doi: 10.1007/s10067-007-0767-y. Epub 2007 Oct 16.

Abstract

SAPHO syndrome is a rare entity that compromises the skeletal system (arthritis-osteitis) and is associated with various dermatological conditions such as palmoplantaris pustulosis (PPP) and acne. We present the case of a 39-year-old man with invalidating arthritis derived from a SAPHO syndrome and hypothyroidism (after radioiodine treatment for a Graves' disease). Due to the severity and refractoriness of his disease, we decided to use infliximab. He showed a prompt and prolonged response of his joint and cutaneous manifestations after three doses of a tumor necrosis factor alpha (TNF-alpha) blocker. Interestingly, he also decreased his levothyroxine requirements after TNF-alpha blockade therapy.

Publication types

  • Case Reports

MeSH terms

  • Acquired Hyperostosis Syndrome / drug therapy*
  • Adult
  • Antibodies, Monoclonal / therapeutic use*
  • Antirheumatic Agents / therapeutic use*
  • Dose-Response Relationship, Drug
  • Humans
  • Hypothyroidism / drug therapy*
  • Infliximab
  • Male
  • Remission Induction
  • Thyroxine / therapeutic use*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Thyroxine